Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from DBV Technologies SA – American ( (DBVT) ) is now available.
On December 16, 2025, DBV Technologies announced positive topline results from its Phase 3 VITESSE trial of the VIASKIN® Peanut Patch for treating peanut-allergic children aged 4 to 7 years. The trial met its primary endpoint, showing a statistically significant treatment effect, with 46.6% of children in the treatment group meeting the response criteria compared to 14.8% in the placebo group. The safety profile was consistent with previous studies, and the company plans to submit a Biologics License Application in the first half of 2026. This milestone triggers the acceleration of the exercise period for certain warrants, reflecting a significant advancement in DBV’s mission to provide a well-tolerated, non-invasive treatment option for peanut allergies.
The most recent analyst rating on (DBVT) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.
Spark’s Take on DBVT Stock
According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.
DBV Technologies SA’s overall stock score is primarily impacted by its financial instability, characterized by declining revenues and persistent losses. While technical indicators show some positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on DBVT stock, click here.
More about DBV Technologies SA – American
DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently concentrating on its proprietary VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy (EPIT), a new class of non-invasive treatment designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin.
Average Trading Volume: 240,226
Technical Sentiment Signal: Buy
Current Market Cap: $759.4M
For an in-depth examination of DBVT stock, go to TipRanks’ Overview page.